Skip to main content
TipRanks
Go Ultimate75% OFF

Lyka Labs Limited (LYKALABS) AI Stock Analysis

1 Followers
IN:LYKALABS

Lyka Labs Limited

(NSE:LYKALABS)

Select Model
Rating:50.8Neutral
Price Target:INR 91.00â–¼(-1.64% Downside)
Action:reiterated
Date:08/26/26

The stock’s moderate overall score reflects weak and volatile profitability and cash generation as the dominant concern, despite an improved capital structure, while a currently strong price trend and positive technical setup provide support but are tempered by loss-driven, hard-to-interpret valuation and elevated volatility.

Positive Factors
Debt ReductionSubstantial debt reduction and positive equity improve financial flexibility compared with earlier periods of heavy leverage. This can lower financing pressure, strengthen resilience through operating volatility, and provide a more stable foundation for funding pharmaceutical activities.
Negative Factors
Revenue and Profitability WeaknessThe latest reversal from growth and profitability to lower revenue and substantial losses shows that earnings remain unstable. Continued volatility can weaken internal funding, make operational planning harder, and reduce confidence in durable profit generation.

Lyka Labs Limited (LYKALABS) vs. iShares MSCI India ETF (INDA)

-50%-40%-30%-20%-10%0%10%20%IN:LYKALABS+11.34%INDA-2.43%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 3.38B
Dividend Yield
―
Average Volume (3M)
5,291
Price to Earnings (P/E)
-77.8
Beta (1Y)
1.28
Revenue Growth
6.10%
EPS Growth
-309.17%
Country
India
Employees
648
Sector
General
Sector Strength
55
Industry
Biotechnology

Lyka Labs Limited Business Overview & Revenue Model

Company Description

Established in 1976 and headquartered in Mumbai, India, Lyka Labs Limited is a pharmaceutical firm specializing in the development, manufacturing, and marketing of a wide array of pharmaceutical formulations and active pharmaceutical ingredients (API...

Lyka Labs Limited Financial Statement Overview

Summary

Overall financial quality is weak: revenue has recently declined, profitability has swung from solid profit to sizeable losses in 2026, and free cash flow has been negative and worsening, partially offset by a meaningfully improved balance sheet with lower debt and positive equity.

Income Statement

32Negative

Balance Sheet

61Positive

Cash Flow

28Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue1.38B1.28B1.41B1.05B916.90M1.84B
Gross Profit311.71M279.37M851.35M599.41M152.84M1.30B
EBITDA-5.41M-36.57M201.67M167.59M128.47M1.01B
Net Income-88.99M-100.32M80.12M-24.89M-132.12M390.00M
Balance Sheet
Total Assets01.75B1.76B1.57B1.52B1.86B
Cash, Cash Equivalents and Short-Term Investments18.93M13.85M13.63M62.91M119.39M170.59M
Total Debt0488.69M391.84M586.50M751.02M1.30B
Total Liabilities-908.31M837.05M726.24M884.59M1.06B1.72B
Stockholders Equity908.31M923.93M1.04B681.54M454.41M133.38M
Cash Flow
Free Cash Flow51.46M-75.25M-137.55M-74.58M7.67M717.33M
Operating Cash Flow136.84M36.06M18.99M17.73M89.53M792.46M
Investing Cash Flow-46.95M-111.03M-117.96M-94.88M73.50M-61.72M
Financing Cash Flow-91.69M75.12M52.92M19.53M-216.43M-631.77M

Lyka Labs Limited Technical Analysis

Technical Analysis SentimentPositive
Last Price92.52

Price Trends

50DMA81.87Positive
100DMA75.82Positive
200DMA68.85Positive

Market Momentum

MACD2.61Negative
RSI73.95Negative
STOCH100.00Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:LYKALABS, the sentiment is Positive. The current price of 92.52 is above the 20-day moving average (MA) of 81.74, above the 50-day MA of 81.87, and above the 200-day MA of 68.85, indicating a bullish trend. The MACD of 2.61 indicates Negative momentum. The RSI at 73.95 is Negative, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:LYKALABS.

Lyka Labs Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:LYKALABS against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:SUPRIYAIN:SUPRIYA66NeutralINR 50.26B28.18―0.16%23.00%-2.84%
IN:HALEOSLABSIN:HALEOSLABS58NeutralINR 4.78B37.59―0.09%-0.99%-30.72%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IN:DCALIN:DCAL55NeutralINR 18.59B26.57――-0.11%-184.93%
IN:LYKALABSIN:LYKALABS51NeutralINR 3.28B-77.84――6.10%-309.17%
IN:ZOTAIN:ZOTA45NeutralINR 39.61B-38.40―0.08%68.95%-55.82%
IN:PANACEABIOIN:PANACEABIO37UnderperformINR 21.64B111.61――19.43%―

* General Sector Average

Performance Comparison

-50%0%50%IN:LYKALABSIN:DCALIN:PANACEABIOIN:HALEOSLABSIN:SUPRIYAIN:ZOTADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:LYKALABS and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:LYKALABSLyka Labs Limited92.5212.0414.96%
IN:DCALDishman Carbogen Amcis Ltd.115.85-116.25-50.09%
IN:PANACEABIOPanacea Biotec Limited336.25-12.30-3.53%
IN:HALEOSLABSSMS Lifesciences India Ltd.1608.95261.5219.41%
IN:SUPRIYASupriya Lifescience Limited620.25-124.71-16.74%
IN:ZOTAZota Health Care Ltd.1288.00-339.28-20.85%

Lyka Labs Limited Corporate Events

Lyka Labs Files SEBI Dematerialisation Compliance Certificate for September Quarter

Oct 8, 2026

Lyka Labs Limited has submitted to the stock exchanges a compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30 September 2026. The company forwarded a certificate from its...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 26, 2026